Nothing Special   »   [go: up one dir, main page]

UY26529A1 - GLIBURIDE COMPOSITION. - Google Patents

GLIBURIDE COMPOSITION.

Info

Publication number
UY26529A1
UY26529A1 UY26529A UY26529A UY26529A1 UY 26529 A1 UY26529 A1 UY 26529A1 UY 26529 A UY26529 A UY 26529A UY 26529 A UY26529 A UY 26529A UY 26529 A1 UY26529 A1 UY 26529A1
Authority
UY
Uruguay
Prior art keywords
gliburide
composition
glyburide
physical form
methoxybenzamide
Prior art date
Application number
UY26529A
Other languages
Spanish (es)
Inventor
Gillian Cave
Sarah J Nicholson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26529A1 publication Critical patent/UY26529A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una forma física del fármaco conocido como gliburida, también conocido como glibenclamida, y definido químicamente como 5-cloro-N-2-4- (ciclohexilamino)-carbonil¨amino sulfonil fenil etil -2-metoxibenzamida (Merck Index, Décima Edición, P. 642), así como a formas de dosificación, por ejemplo, tabletas y cápsulas, que incorporan esa forma física de la gliburida.The present invention relates to a physical form of the drug known as glyburide, also known as glibenclamide, and chemically defined as 5-chloro-N-2-4- (cyclohexylamino) -carbonyl¨amino sulfonyl phenyl ethyl -2-methoxybenzamide (Merck Index, Tenth Edition, P. 642), as well as dosage forms, eg, tablets and capsules, which incorporate that physical form of glyburide.

UY26529A 2000-01-14 2001-01-11 GLIBURIDE COMPOSITION. UY26529A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
UY26529A1 true UY26529A1 (en) 2001-08-27

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26529A UY26529A1 (en) 2000-01-14 2001-01-11 GLIBURIDE COMPOSITION.

Country Status (37)

Country Link
US (2) US20010036479A1 (en)
EP (1) EP1250321B1 (en)
JP (1) JP4787446B2 (en)
KR (1) KR100739906B1 (en)
CN (1) CN1210258C (en)
AR (1) AR031547A1 (en)
AT (1) ATE330937T1 (en)
AU (1) AU771705B2 (en)
BG (1) BG65782B1 (en)
BR (1) BR0107564A (en)
CA (1) CA2397294C (en)
CY (1) CY1106328T1 (en)
CZ (1) CZ20022429A3 (en)
DE (1) DE60120916T2 (en)
DK (1) DK1250321T3 (en)
EE (1) EE05020B1 (en)
ES (1) ES2264967T3 (en)
GE (1) GEP20043299B (en)
HU (1) HU228825B1 (en)
IL (2) IL150383A0 (en)
LT (1) LT5024B (en)
LV (1) LV12914B (en)
MX (1) MXPA02006835A (en)
MY (1) MY128577A (en)
NO (1) NO328152B1 (en)
NZ (1) NZ519920A (en)
PT (1) PT1250321E (en)
RO (1) RO121381B1 (en)
RU (1) RU2244707C2 (en)
SK (1) SK286925B6 (en)
TN (1) TNSN01005A1 (en)
TR (1) TR200201798T2 (en)
TW (1) TWI287989B (en)
UA (1) UA73968C2 (en)
UY (1) UY26529A1 (en)
WO (1) WO2001051463A1 (en)
ZA (1) ZA200205528B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
EP1465628A2 (en) * 2002-03-21 2004-10-13 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
HUE028576T2 (en) 2003-10-31 2016-12-28 Takeda Pharmaceuticals Co Solid preparation comprising pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
JP2007534704A (en) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 Oral sustained release tablet composition and method for producing the same
CN100455279C (en) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 Oral administered sustained release lozenge composition and its preparation method
CN100341495C (en) * 2004-12-29 2007-10-10 三九医药股份有限公司 Solid dispersion and preoral combination of glibenclamide and preparation method
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
CN101287467B (en) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 Methods and formulations for modulating Lyn kinase activity and treating related disorders
JP5113752B2 (en) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Methods and formulations for modulating the activity of LYN kinase and treating related diseases
JP2009537478A (en) * 2006-05-13 2009-10-29 ノヴォ ノルディスク アクティーゼルスカブ Tablet formulation containing repaglinide and metformin
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en) 2008-10-22 2014-11-11 University of Pittburgh—Of the Commonwealth System of Higher Education Radioprotective agents
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (en) * 2012-07-31 2012-10-24 南京正科制药有限公司 Repaglinide tablet and preparation method thereof
CN103142521B (en) * 2013-03-21 2014-06-25 西南药业股份有限公司 Glibenclamide tablet and preparation method thereof
CN104127423A (en) * 2014-07-30 2014-11-05 沈阳药科大学 Gliquidone derivative, preparation method and application thereof
CN104127424A (en) * 2014-07-30 2014-11-05 沈阳药科大学 Glibenclamide derivative, preparation method and application thereof
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes
CN113143940A (en) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 Preparation method of antidiabetic pharmaceutical composition
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (en) 1963-10-19 1965-01-14 Hoechst Ag Process for the preparation of benzenesulfonylureas
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (en) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim New form of preparation of N-4- [2- (5-chloro-2-methoxybenzamido) ethyl] -phenyl-sulfonyl-N'-cyclohexylurea
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (en) 1988-10-01 1991-09-12 Hoechst Ag METHOD FOR MICRONIZING GLIBENCLAMIDE
RU2026670C1 (en) 1988-10-05 1995-01-20 Дзе Апджон Компани Method of preparing of fine-dispersed solid pharmaceutical substance
US5258185A (en) 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5932245A (en) * 1991-12-05 1999-08-03 Alfatec Pharma Gmbh Gelatin or collagen hydrolysate containing drug formulation that provides for immediate release of nanoparticle drug compounds
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
DE4323636A1 (en) * 1993-07-15 1995-01-19 Hoechst Ag Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (en) * 1995-11-14 1997-10-27 Gentili Ist Spa GLIBENCLAMIDE-METFORMIN ASSOCIATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND THEIR USE IN THE TREATMENT OF TYPE DIABETES MELLITUS
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (en) * 1997-05-22 1998-11-26 Basf Ag Process for the preparation of small-scale preparations of biologically active substances
DE122007000054I1 (en) 1997-06-18 2007-12-13 Smithkline Beecham Plc Treatment of diabetes with thiazolidinediones and metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DK0996429T3 (en) * 1997-10-27 2003-05-26 Merck Patent Gmbh Solid solutions and solid dispersions in water heavily soluble drugs
PT974356E (en) 1998-07-15 2004-02-27 Merck Sante Sas TABLETS COMPREHENSING A METFORMIN AND GLIBENCLAMIDE COMBINATION
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
EE05020B1 (en) 2008-06-16
US20010036479A1 (en) 2001-11-01
ES2264967T3 (en) 2007-02-01
HUP0203852A2 (en) 2003-04-28
CZ20022429A3 (en) 2003-06-18
IL150383A0 (en) 2002-12-01
AU2474001A (en) 2001-07-24
AU771705B2 (en) 2004-04-01
CA2397294A1 (en) 2001-07-19
ATE330937T1 (en) 2006-07-15
BG65782B1 (en) 2009-11-30
TNSN01005A1 (en) 2005-11-10
CA2397294C (en) 2011-03-22
CN1395560A (en) 2003-02-05
EE200200393A (en) 2003-10-15
LT2002085A (en) 2003-01-27
CY1106328T1 (en) 2011-10-12
RU2244707C2 (en) 2005-01-20
KR20020073169A (en) 2002-09-19
BG106870A (en) 2003-03-31
PL356210A1 (en) 2004-06-14
US20030185880A1 (en) 2003-10-02
MY128577A (en) 2007-02-28
SK9832002A3 (en) 2003-07-01
LV12914B (en) 2003-01-20
RO121381B1 (en) 2007-04-30
UA73968C2 (en) 2005-10-17
TWI287989B (en) 2007-10-11
US6830760B2 (en) 2004-12-14
ZA200205528B (en) 2003-10-10
LT5024B (en) 2003-06-25
EP1250321A1 (en) 2002-10-23
NO20023367D0 (en) 2002-07-12
JP2003519681A (en) 2003-06-24
DK1250321T3 (en) 2006-07-31
EP1250321B1 (en) 2006-06-21
PT1250321E (en) 2006-09-29
BR0107564A (en) 2002-10-01
IL150383A (en) 2007-03-08
AR031547A1 (en) 2003-09-24
NZ519920A (en) 2004-06-25
GEP20043299B (en) 2004-03-10
CN1210258C (en) 2005-07-13
JP4787446B2 (en) 2011-10-05
HUP0203852A3 (en) 2005-05-30
DE60120916T2 (en) 2007-02-15
NO328152B1 (en) 2009-12-21
MXPA02006835A (en) 2003-01-28
KR100739906B1 (en) 2007-07-16
NO20023367L (en) 2002-09-04
TR200201798T2 (en) 2002-11-21
HU228825B1 (en) 2013-05-28
WO2001051463A1 (en) 2001-07-19
RU2002121626A (en) 2004-01-10
SK286925B6 (en) 2009-07-06
DE60120916D1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
UY26529A1 (en) GLIBURIDE COMPOSITION.
BR0207726A (en) Pharmaceutical Salts
BR0206627A (en) Pharmaceutical Formulation
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
AR065970A2 (en) A SOLID ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND GLIBENCLAMIDE AND USE OF SUCH COMPOSITION
AR022008A1 (en) A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR037407A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS TYPE II DIABETES
UA108594C2 (en) Single dosage pharmaceutical form
AR049083A1 (en) PROCESS FOR THE PREPARATION OF A SOLID PROOF OF DOSAGE FORM OF ABUSE
ECSP077999A (en) FORMULATIONS OF A MODIFIED LIBERATION BUPROPION SALT
PA8557001A1 (en) NEW PIRROLIDINE DERIVATIVES
GT199900203A (en) CELECOXIB COMPOSITIONS.
AR038527A1 (en) DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS ACTIVE INGREDIENT
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
GT200400087A (en) AGENTS TO COMBAT PARASITES IN ANIMALS.
GT200200247A (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRA-CYCLE [10.3.0 2,11.0 4,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENO
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
ES2178896T3 (en) NEW FORM OF SALT OF PANTOPRAZOL.
BRPI0620229A8 (en) formulation
HN2003000183A (en) DIFENILAZETIDINONAS REPLACED IN RING PROCEDURE FOR PREPARATION, MEDICATIONS THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE.
BR0212931A (en) Metformin-containing prolonged release pharmaceutical composition
UY27727A1 (en) NEW PHARMACEUTICAL COMPOSITION-
CL2004001843A1 (en) COMBINATION OF (A) AT LEAST A 2,5-DIHYDROBENCENOSULPHONIC DERIVATIVE, AS CALCIUM DOBEYLATE, ETHAMSYLATE AND PERSILATE, AND (B) AT LEAST A MODULATOR OF POTASSIUM CHANNELS, PHARMACEUTICAL COMPOSITION CONTAINING AND USE AS A MEDICATION IN PROFILA
AR036085A1 (en) DOSAGE FORMS AND PROCEDURE FOR MANUFACTURING
BRPI0520821A2 (en) fenofibrate pharmaceutical formulations with improved bioavailability

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20130711